Compare BridgeBio Pharma Inc (BBIO) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Morgan Stanley — how do they compare? BridgeBio Pharma Inc trades at $78.3 (market cap $15.25B), while Morgan Stanley trades at $190.65 (market cap $297.99B). The key difference: Morgan Stanley is far larger — about 19.5× BridgeBio Pharma Inc's market cap, and Morgan Stanley pays a 2.41% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold BridgeBio Pharma Inc for 65 Days and Morgan Stanley for 88 Days on average.
| BBIO | MS | |
|---|---|---|
Market Cap | $15.25B | $297.99B |
Volume | 1,149,255 | 4,435,939 |
Sector | Health | Financials |
52-Week High | $90.17 | $228.42 |
52-Week Low | $63.30 | $154.37 |
Typical Hold Time | 65 Days | 88 Days |
Enterprise Value | $17.15B | $691.65B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $78.30, up 0.17% with strong bullish technical signals from moving averages. The company shows impressive revenue growth from $502M in 2025 to projected $946M in 2026, though it remains unprofitable with negative net margins. Recent news highlights four global therapy launches planned by 2027, with Attruby nearing blockbuster status and positive clinical data for acoramidis showing cardiac benefits.
Investment outlook balances high growth potential against significant financial risks. While analyst consensus is strongly bullish (89% buy ratings) with $110.18 price target, the company faces substantial losses, negative equity, and heavy debt load. Success depends on successful commercialization of pipeline drugs and achieving profitability targets amid competitive biopharmaceutical landscape.
Morgan Stanley (MS) trades at $190.65, up 0.78% with neutral technical signals. The company demonstrates strong fundamental performance with three consecutive quarterly earnings beats and robust profitability metrics including 27.33% net income margin and 19.12% ROE. Revenue growth continues with 2025 revenue reaching $66.0B, while analyst consensus remains bullish with a $210.60 price target representing 10.5% upside potential.
The outlook remains positive given consistent earnings outperformance and growth opportunities in wealth management and AI financing. Key risks include volatile cash flow patterns with negative operating cash flow in 2025 and elevated debt levels at 26.1% debt-to-asset ratio. The stock presents a compelling value proposition at 15.12 P/E with strong institutional support from 29 buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
